News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cerespir Announces The Inauguration Of Its Clinical Advisory Board



2/21/2014 8:52:34 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

NEW YORK, Feb. 21, 2014 (GLOBE NEWSWIRE) -- CereSpirâ„¢ Incorporated, a company developing the first-in-class microglial modulator CHF 5074 as a potential treatment for Alzheimer's disease (AD), today announced the inauguration of its Clinical Advisory Board (CAB). Rachelle Doody, MD, PhD, Baylor College of Medicine, is serving as Chair of the Board. The Advisory Board also includes Steven H. Ferris, PhD, New York University Langone Medical Center; Michael Grundman, MD, MPH, President and CEO, Global R&D Partners, LLC; Eric M. Reiman, MD, Executive Director, Banner Alzheimer's Institute; and Lon S. Schneider, MD, MS, Keck School of Medicine of USC.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
Cerespir
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES